Funding for this research was provided by:
Department of Health, Australian Government (N/A)
Received: 15 December 2019
Accepted: 21 October 2020
First Online: 31 October 2020
Ethics approval and consent to participate
: This PaCCSC RCT was approved by the following ethics committees across Australia (see ExternalRef removed).- Repatriation General Hospital Research and Ethics Committee, South Australia (EC00191)- Mater Health Services Human Research Ethics Committee, Mater Health Service, Queensland (EC00332)- Ballarat Health Services & St John of God Health Care Ethics Committee, Ballarat Health Services, Victoria (EC00326)- Alfred Hospital Ethics Committee, Victoria (EC00266)- Hollywood Private Hospital Research Ethics Committee, Western Australia (EC00266)- St John of God Health Care Ethics Committee, Western Australia (EC00414)- Peter MacCallum Cancer Centre Ethics Committee, Peter MacCallum Cancer Centre, Victoria (EC00235)Participants provided written informed consent.
: Not applicable.
: Professor Currow is an unpaid member of an advisory board for Helsinn Pharmaceuticals, is a consultant to Specialized Therapeutics and Mayne Pharma and received intellectual property payments from Mayne Pharma. All other authors declare no conflicts of interest.